Alina Markova is a Dermatology physician affiliated with Memorial Sloan Kettering Cancer Center. OpenAlex indexes 149 publications with 2,000 citations (h-index 22); ClinicalTrials.gov lists 9 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
- A Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors
Sponsor: Memorial Sloan Kettering Cancer Center
- A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
Sponsor: Memorial Sloan Kettering Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- NovocureProgram year20252 paymentsResearch$184,795openpaymentsdata.cms.gov ↗
- IncyteProgram year20252 paymentsResearch$154,366openpaymentsdata.cms.gov ↗
- AstraZenecaProgram year20251 paymentResearch$120,512openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors
Journal for ImmunoTherapy of Cancer
2025 - Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy
Journal for ImmunoTherapy of Cancer
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
Mark Kris, MD
Memorial Sloan Kettering Cancer Center
Robert Modlin, MD
University of California, Los Angeles
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”